目标翻译:化疗诱发周围神经病变治疗方法开发中的动物临床前模型综述。
Targeting translation: a review of preclinical animal models in the development of treatments for chemotherapy-induced peripheral neuropathy.
发表日期:2023 Mar 30
作者:
Daniel White, Munawwar Abdulla, Susanna B Park, David Goldstein, Gila Moalem-Taylor, Justin G Lees
来源:
Disease Models & Mechanisms
摘要:
化疗在癌症的治疗中的扩大应用,同时导致了一个人数庞大且不断增加的癌症幸存者队伍,他们因为化疗引起的周围神经病变(CIPN)而长期残疾。白金类药物,紫杉醇,长春碱,硼替佐米和沙利度胺等常规药物与CIPN有关。这些不同类别的化疗药物,具有各种神经毒性机制,通常会导致患者患上广泛的神经病理症状,包括慢性麻木,感觉异常,丧失本体感知或振动感觉和神经痛。多年来,许多研究小组对这种疾病进行了大量研究,提供了重要见解。尽管有了这些进展,目前对CIPN没有有效的治疗方法,只有双重血清素-去甲肾上腺素再摄取抑制剂度洛西汀被临床指南推荐作为治疗疼痛性CIPN的症状性治疗。在本综述中,我们研究当前的预临床模型,分析其转化相关性和价值。动物模型对于更好地理解CIPN的发病机理起到了关键作用。然而,研究人员开发适当的预临床模型以发现可转化的治疗方法是具有挑战性的。进一步发展目标是转化相关性的预临床模型,将会促进在CIPN研究中的预临床结果的价值。本文章受版权保护。所有权利已保留。
The expanding use of chemotherapy in curative cancer treatment has simultaneously resulted in a substantial and growing cohort of cancer survivors with prolonged disability from chemotherapy-induced peripheral neuropathy (CIPN). CIPN is associated with several commonly prescribed chemotherapeutics, including taxanes, platinum-based drugs, vinca alkaloids, bortezomib and thalidomide. These distinct classes of chemotherapeutics, with their varied neurotoxic mechanisms, often cause patients to suffer from a broad profile of neuropathic symptoms including chronic numbness, paraesthesia, loss of proprioception or vibration sensation and neuropathic pain. Decades of investigation by numerous research groups has provided substantial insights describing this disease. Despite these advances there is currently no effective curative or preventative treatment option for CIPN and only the dual serotonin-norepinephrine reuptake inhibitor Duloxetine is recommended by clinical guidelines for the symptomatic treatment of painful CIPN.In this review, we examine current preclinical models, with our analysis focused upon translational relevance and value.Animal models have been pivotal in achieving a better understanding of the pathogenesis of CIPN. However, it has been challenging for researchers to develop appropriate preclinical models that are effective vehicles for the discovery of translatable treatment options.Further development of preclinical models targeting translational relevance will promote value for preclinical outcomes in CIPN studies. This article is protected by copyright. All rights reserved.This article is protected by copyright. All rights reserved.